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ABSTRACT
Objectives: Chronic kidney disease is, increasingly, both a contributor to
premature deaths and a ﬁnancial burden to the health system, and is
estimated to affect between 10% and 15% of the adult population in
Western countries. Hypertension and, in particular diabetes, are signiﬁcant
contributors to the global burden of chronic kidney disease. Although it
might increase costs, screening for, and improved management of, persons
at increased risk of progressive kidney disease could improve health out-
comes. We therefore sought to estimate the costs and health outcomes of
alternative strategies to prevent end-stage kidney disease, compared with
usual care.
Methods: A Markov model comparing: 1) intensive management versus
usual care for patients with suboptimally managed diabetes and hyperten-
sion; and 2) screening for and intensive treatment of diabetes, hyperten-
sion, and proteinuria versus usual care was developed. Intervention
effectiveness was based on published meta-analyses and randomized con-
trolled trial data; costs were measured from a central health-care funder
perspective in 2008 Australian dollars ($A), and outcomes were reported
in quality-adjusted life-years (QALYs).
Results: Intensive treatment of inadequately controlled diabetes was both
less costly (an average lifetime saving of $A133) and more effective (with
an additional 0.075 QALYs per patients) than conventional management.
Intensive management of hypertension had an incremental cost-
effectiveness ratio (ICER) $A2588 per QALY gained. Treating all known
diabetics with angiotensin-converting enzyme (ACE) inhibitors was both
less costly (an average lifetime saving of $A825 per patient) and more
effective than current treatment (resulting in 0.124 additional QALYs per
patient). Primary care screening for 50- to 69-year-olds plus intensive
treatment of diabetes had an ICER of $A13,781 per QALY gained.
Primary care screening for hypertension (between ages 50 and 69 years)
plus intensive blood pressure management had an ICER of $A491 per
QALY gained. Primary care screening for proteinuria (between ages 50
and 69 years) combined with prescription of an ACE inhibitor for all
persons showing proteinuria and all known diabetics had an ICER of
$A4793 per QALY gained.
Conclusions: Strategies combining primary care screening of 50- to
69-year-olds for proteinuria, diabetes, and hypertension followed by the
routine use of ACE inhibitors, and optimal treatment of diabetes and
hypertension, respectively, have the potential to reduce death and end-
stage kidney disease and are likely to represent good value for money.
Keywords: chronic kidney disease, cost–utility analysis, economic evalua-
tion, Markov model.
Introduction
Chronic kidney disease (CKD) is a signiﬁcant global health
concern [1] affecting approximately 10% to 15% of the adult
populations of many Western countries such as Australia and the
United States, and up to 20% of the adult Japanese population
[2–4]. Health consequences are substantial, with sufferers at
increased risk of cardiovascular disease and early death [5,6].
Some will progress to end-stage kidney disease (ESKD) requiring
dialysis or transplantation [7]. The number of patients dependent
on dialysis for survival exceeds 1.4 million globally and is
increasing by 8% per annum [1]. The cost of dialysis in the
United States alone is projected to exceed $US29 billion per
annum by 2010 [5]. Given the relative proportions of CKD and
ESKD, the cost of predialysis CKD is estimated to double that of
dialysis [8].
Prevention, early detection, and intervention may prevent
onset of CKD and reduce the likelihood of CKD progression. In
most countries, diabetes is the primary cause of CKD and ESKD
[9] with 20% to 40% of patients with type 1 or type 2 diabetes
developing nephropathy [10]. Hypertension is strongly associ-
ated with CKD [11]. The onset and progression of CKD, as well
as cardiovascular consequences might be reduced through
intensive control of glycemia and hypertension [12–14].Where
CKD occurs with proteinuria, angiotensin-converting enzyme
(ACE) inhibitors or angiotensin II-receptor blockers (ARB)
further reduce CKD progression, cardiovascular morbidity, and
mortality [15–17].
International trial evidence suggests that early detection and
management of CKD and risk factors such as diabetes, hyperten-
sion, and proteinuria may be cost-effective [18–24]. Despite this,
substantial proportions of the Australian population have inad-
equately controlled diabetes and hypertension [25], with few
Australian analyses that examine the cost-effectiveness of early
detection and management of CKD risk factors [23].
The international nephrology community is increasingly
advocating a comprehensive approach to the prevention of CKD,
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avoiding or delaying the onset of CKD in at-risk individuals, and
intervening to prevent progression [1,26]. Nevertheless, this call
to action lacks supporting cost-effectiveness data. Existing
studies of isolated interventions have not considered the costs
and health outcome implications of a comprehensive approach to
prevention, early detection, and management, encompassing
primary care screening coupled with improved pharmacotherapy.
We assessed, from the perspective of a health-care funder, the
health outcomes (measured in terms of quality-adjusted life-years
[QALYs]) and incremental costs of intensive management of
patients known to have diabetes and hypertension, with and
without early detection of new patients at risk for CKD, com-
pared with current practice.
Methods
We developedMarkov models to simulate the annual progression
of patients from the development of risk factors (speciﬁcally
diabetes, hypertension, and proteinuria) through CKD, to ESKD
and death (Fig. 1).We used these models to calculate the costs and
health outcomes of CKD management strategies comprising of:
(1) improvedmanagement of patients with diabetes and hyperten-
sion; and (2) primary care–based population screening of persons
aged 25 or older for early detection of hypertension, diabetes (with
orwithoutmicroalbuminuria), and proteinuria (Table 1). Lacking
evidence on which to base an estimate of the magnitude of the
combined effectiveness of optimal control of diabetes, hyperten-
sion, and proteinuria, we modeled these interventions separately.
Health outcomes were measured in terms of QALYs, and costs
were measured in Australian dollars ($A) from a health funder
perspective; all future costs and health outcomes were discounted
at 5% per annum [27]. All rates were converted to annual
probabilities. Additional details are available in reference [28] and
as Supporting information at: http://www.ispor.org/Publications/
value/ViHsupplementary/ViH13i2_Howard.asp
Model Structure and Assumptions
Structure. Markov models were constructed for each of the
treatment and screening strategies in Table 1. Models incorpo-
rate uncertainty using Monte Carlo simulation and probabilistic
sensitivity analysis, with a cycle length of 1 year; patients were
followed over a lifetime (until death or age 95 years). Patients
progress through a series of annual, age-speciﬁc transition prob-
abilities, over their remaining lifetime, to determine whether they
die, have a nonfatal cardiac event, stay in the current health state,
or progress to ESKD. Patients with diabetes (with or without
hypertension) progress through stages of diabetes with varying
levels of nephropathy (diabetes with no albuminuria, to diabetes
with microalbuminuria, to diabetes with macroalbuminuria),
and eventually to ESKD requiring renal replacement therapy
(RRT). In all diabetes health states, each year, patients have a
chance of experiencing a nonfatal cardiac event, of dying from
cardiovascular disease, dying from other causes, having progres-
sion of their nephropathy, or remaining in the same health state.
For patients with diabetes and no albuminuria, progression of
nephropathy meant the development of microalbuminuria; for
patients with microalbuminuria, progression meant the develop-
ment of macroalbuminuria, and for patients with existing
macroalbuminuria, progression meant development of ESKD
requiring RRT. For hypertension and proteinuria states, patients
have an annual probability of experiencing a nonfatal cardiovas-
cular event, of dying from cardiovascular disease, dying from
noncardiovascular causes, remaining in the same health state, or
progressing to ESKD requiring RRT. Figure 1 indicates CKD in a
dotted box, indicating that it is not modeled explicitly as a health
state in its own right, because it is generally asymptomatic, but
rather to acknowledge that it is the clinical precursor to devel-
oping ESKD requiring RRT. Once patients reach ESKD requiring
RRT, they receive dialysis or transplant. Patients on dialysis may
receive a subsequent transplant, can experience a nonfatal car-
diovascular event, die of cardiovascular or noncardiovascular
causes, remain on dialysis, or can elect to discontinue active RRT,
and instead receive conservative management until they die.
Patients with a functioning transplant may return to dialysis after
a graft failure, receive another transplant after graft failure, can
experience a nonfatal cardiovascular event, die of cardiovascular
or noncardiovascular causes, or remain alive with a functioning
transplant.
For screening interventions, patients start in a “population”
(undiagnosed) state from which they might be found to have the
risk factor (by screening or clinical diagnosis); after diagnosis
patients progress through the health states above. Patients can, in
any cycle, experience a nonfatal cardiovascular event, or die of
cardiovascular or noncardiovascular related causes.
Assumptions. For all interventions, the decision tree represented
a choice between the intervention and current management. The
AusDiab study was used to inform the modeled populations.
AusDiab is an Australian population-representative cohort study
that identiﬁes, through oral glucose tolerance tests cases of diag-
nosed and undiagnosed type 2 diabetes, and elicits other risk
factors for CKD [2,25,29,30]. The AusDiab study was also used
to estimate: 1) the age-speciﬁc population prevalence of risk
factors; 2) the prevalence of comorbidities (e.g., the number of
people with diabetes and hypertension); 3) numbers of known
Table 1 Interventions modeled
Patients Intervention Comparator
Improved management in known/existing patients
1 Diabetics (hypertension) Intensive glucose control Routine glucose control
2 Diabetics (hypertension) Addition of ACEi Current practice
3 Hypertensive patients (diabetes) Intensive BP control Routine BP control
Primary care–based screening for CKD risk factors
4 Diabetes Fasting BSL (with OGTT if screen-positive) + intensive glycemic control of new
and known but uncontrolled patients
Current practice
5 Hypertension BP measurement in GP practice + intensive BP control of new and known but
uncontrolled patients
Current practice
6 Proteinuria Protein detection with urine dipstick (with protein : creatinine ratio if
screen-positive) + treatment with ACEi for new and known patients + ACEi
for all diabetics
Current practice
ACEi, angiotensin-converting enzyme inhibitor; BP, blood pressure; BSL, blood sugar level; OGTT, oral glucose tolerance tests.
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(preexisting disease before AusDiab study entry) and new
patients (disease diagnosed at AusDiab study entry); and 4) the
proportion of patients with controlled and uncontrolled disease
[25,30]. In AusDiab, disease control thresholds were deﬁned as
HbA1c of 7.0 or no for diabetes and systolic blood pressure of
140 mmHg or no, or diastolic pressure of 90 mmHg or no for
hypertension. Patients with uncontrolled diabetes were at an
increased risk of events, dependent on HbA1c levels [31,32].
Additional details on data sources are provided in the Supporting
information and in reference [28].
Treatment. The age and risk factor proﬁle of the modeled popu-
lation for intensive treatment strategies was representative of the
Australian treatment population aged 25 years or older, based on
the AusDiab study. For treatment interventions, patients in the
comparator arm were assumed to be managed according to
current Australian practice. The proportion of patients who are
“uncontrolled” on conventional management for each risk factor
is based on AusDiab data. In the intervention arm, the beneﬁts
(in terms of reduction of events) are applied to only the patients
who have uncontrolled risk factors. This assumes that those
patients with controlled disease will gain no additional beneﬁt
from the intervention, in terms of avoidance of events. This
assumption means that the estimation of beneﬁt from more
intensive intervention is likely to be a relatively conservative
estimate of the population beneﬁt.
Screening. For screening strategies, age and sex distributions of
the entire Australian population aged 25 years or older formed the
basis for the modeled population [33]. The proportion of the
population with undiagnosed risk factors was based on AusDiab
data (as above). For the screening interventions, it was assumed
that a proportion of patients in the comparator arm would
continue to receive clinical diagnoses; in the screening arm a
patient could receive a diagnosis by screening, or by clinical
diagnosis. As with treatment interventions, the beneﬁts are
applied to only the patients who have uncontrolled risk factors in
the intervention arm. Discussion of the estimation of event rates in
various patient populations is provided as Supporting information
at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i2_Howard.asp
All event rates, costs, and outcomes for patients requiring
RRT are based on the actual treatment and outcome probabilities
observed in the Australian national cohort of ESKD patients
commencing treatment during 1996 to 2000 [11].
Strategies Modeled
Improved management of known patients with CKD risk factor
(“treatment”). Three strategies for improving the management
of these patients were modeled: 1) intensive glycemic control
(compared with routine control); 2) the prescription of an ACE
inhibitor for all diabetic patients (regardless of glycemic control
or hypertension status); and 3) intensive blood pressure control
(compared with routine blood pressure control). The effective-
ness of interventions was based on data from meta-analyses or
randomized controlled trials (Table 2) and was applied to the
proportion of the population in the intervention arm whose
disease remained uncontrolled with conventional management.
Regimens are shown in Table 4.
Primary care–based screening strategies for CKD risk factors
(“screening”). All screening strategies were based on annual
primary care–based screening, offered to people aged between 50
and 69 years. In the base-case, it was assumed that 75% of
people offered screening would participate [24]; the participation
rate was varied in sensitivity analyses. Screening and diagnostic
test characteristics are shown in Table 3. Because the AusDiab
data formed the basis for the proportion of patients with undi-
agnosed disease, the thresholds for screen test positivity were also
based on AusDiab [25,30].
The modeled screening test for diabetes was fasting blood
sugar level. A level >5.5 mmol/L was classiﬁed as positive. After
a positive screen, an oral glucose tolerance test was used as a
diagnostic test. The screening test for hypertension was blood
pressure measurement in a primary care setting (mean of three
measurements), with a threshold of 140/90 mmHg, and was
assumed to be 100% sensitive and speciﬁc (because this is what
determines the provision of antihypertensives). Screening for pro-
teinuria was conducted using a urine dipstick, followed by a
conﬁrmatory diagnostic test (spot urine protein : creatinine ratio
>0.20 mg/mg) for a dipstick result of 1+ or greater.
It is assumed that all screen-positive patients undergo conﬁr-
matory diagnostic tests (diabetes and proteinuria). All screen-
detected disease was treated intensively as described above.
Costs
Costs are reported in 2008 Australian dollars [34–38]. The
analysis took a health-care funder perspective, because Australia
has a centrally funded universal health-care system. Costs of
screening strategies are in Table 3; costs of treatment interven-
tions for risk factors and ESKD are summarized in Table 4.
Table 4 presents a proportion-weighted average annual treat-
ment cost per patient. Nonpharmaceutical health-care resource
utilization for diabetic patients is based on the care practices in
the UKPDS study [18]; the proportion of patients on each class of
hypoglycemic medication in the conventional and intensive man-
agement groups is based on the Australian and New Zealand
ADVANCE study cohort at the end of follow-up (December
2007) [14, (A. Patel and J. Chalmers. ADVANCE Study: man-
agement regimens in Australian and New Zealand patients. Per-
sonal Communication)]. These data are broadly consistent with
the NEFRON study [39]; and the average annual cost of each
class of hypoglycemic used is based on 2008 Pharmaceutical
Beneﬁts Scheme (PBS) utilization and PBS unit cost data. Nonp-
harmaceutical health-care resource utilization for patients with
hypertension is also based on UKPDS [22]; conventional hyper-
tension management is based on a National Prescribing Service
survey [40]. Intensive hypertension management (including
patients with proteinuria) is based on data from the NEFRON
study [41], which reported higher proportions of patients using
all classes of antihypertensives compared with the National Pre-
scribing Service data, and updated to reﬂect the current PBS use
of ﬁxed dose combinations of ACE/diuretic and ARB/diuretic.
The average annual cost of each class of antihypertensive used is
based on 2008 PBS utilization and PBS unit cost data. Patients
with screen-detected proteinuria but no diabetes or hypertension
were treated with an ACE inhibitor, the average annual cost of
ACE inhibitors is based on 2008 PBS utilization and PBS unit
cost data. In addition, costs of fatal and nonfatal cardiovascular
events are based on data from an Australian population [42],
inﬂated to 2008 values [38].
Health-Related Quality of Life (QOL)
Age and health state speciﬁc SF6D utility weights were calculated
from individual patient SF-36 responses from the AusDiab study
[43]; summary values of QOL for a 55-year-old are in Table 2
(additional detail available elsewhere [28]). Utility weights for
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dialysis and transplant health states were based on the published
literature of pre- and post-transplant utility-based health-related
QOL weights [44,45] (Table 2).
Sensitivity Analysis
Probabilistic modeling was conducted. The purpose of probabi-
listic sensitivity analysis is to reﬂect the uncertainty in all input
parameters of a model simultaneously and to describe the impli-
cations of that uncertainty on costs, effects, and cost-effectiveness
[46]. Model parameter distributions were applied as recom-
mended: Gamma distributions were applied to costs, beta distri-
butions were used for probabilities and utilities, and log-normal
distributions were used for relative risks [46].
Results of probabilistic modeling are presented as cost-
effectiveness acceptability curves that plot the likelihood that an
intervention is cost-effective, over a range of decision-makers’
willingness to pay thresholds for each additional health outcome
(QALY) gained, and as scatter plots of the incremental costs and
effects.
Table 2 Effectiveness of improved management strategies and utility values for health states
RR (95% CI)
Source data effectiveness
estimate [supplementary
data sources]
Source data
underlying model of
disease progression
Diabetes Diabetes
Intensive glycemic control [31,55–61]
CVD death 0.88 (0.74–1.04) [14] [[13,50]]
CVD events 0.98 (0.78–1.23) [14] [[13,50]]
Progression from no albuminuria to microalbuminuria 0.91 (0.85–0.98) [14] [[13,50]]
Progression to microalbuminuria and to macroalbuminuria 0.70 (0.57–0.85) [14] [[13,50]]
Progression to macroalbuminuria and to ESKD 0.64 (0.38–1.08) [14] [[13,50]]
Intensive hypertension control
CVD death 0.67 (0.40–1.12) [62] [[63,64]]
CVD events 0.75 (0.61–0.94) [62] [[63,64]]
Progression from no albuminuria to microalbuminuria 0.71 (0.51–0.99) [12] [[65]]
Progression to microalbuminuria and to macroalbuminuria 0.61 (0.31–1.21) [12] [[65]]
Progression to macroalbuminuria and to ESKD 0.61 (0.31–1.21) [12] (assume as for micro to macro)
[[65]]
ACEi for all diabetics*
CVD death 0.67 (0.40–1.12) [62] (assume same as intensive vs.
conventional) [[63,64]]
CVD events 0.59 (0.38–0.91) [66] (assume same relative reduction
for nonfatal events) [[63,64]]
Progression from no albuminuria to microalbuminuria
(no hypertension)
0.72 (0.49–1.06) [66] [[65]]
Progression from no albuminuria to microalbuminuria
(with hypertension)
0.52 (0.31–0.88) [66] [[65]]
Progression from microalbuminuria to macroalbuminuria
(all, regardless of hypertension)
0.45 (0.28–0.71) [16] [[65]]
Progression from macroalbuminuria to ESKD
(all, regardless of hypertension)
0.64 (0.40–1.03) [16] [[65]]
Hypertension Hypertension
Intensive hypertension control (no proteinuria) [57,61,67–69]
CVD death 0.93 (0.77–1.0) [70] [[71]]
CVD events 0.95 (0.76–0.95) [70] [[71]]
Progression to ESKD 0.69 (0.51–0.94) [15] (assume same as ACEi vs. no
ACEi in patients with proteinuria)
ACEi vs. no ACEi (with or without protein)
(used for intensive control in patients with proteinuria)
CVD death 0.80 (0.71–0.80) [70] [[63,64]]
CVD events 0.80 (0.73–0.88) [70] [[63,64]]
Progression to ESKD 0.69 (0.51–0.94) [15]
Proteinuria, no diabetes, no hypertension Proteinuria
ACEi vs. no ACEi [58,67,68,72,73]
CVD death 0.80 (0.71–0.80) [62,70] assume RR is same as for
hypertension no protein
CVD events 0.80 (0.73–0.88) [62,70] (assume RR is same as for
hypertension no protein)
Progression to ESKD 0.66 (0.51–0.85) [15,23]
Utilities (value for age 55) Mean (SD) Source
Diabetes, no albuminuria 0.754 (0.121) [28]
Diabetes, with microalbuminuria 0.725 (0.125) [28]
Diabetes, with macroalbuminuria 0.686 (0.159) [28]
Hypertension 0.744 (0.122) [28]
Proteinuria 0.711 (0.128) [28]
Hemodialyisis 0.443 (0.317) [44]
Peritoneal dialysis 0.569 (0.329) [44]
Transplant 0–12 months 0.7325 (0.27) [45]
Transplant more than 12 months 0.70 (0.27) [45]
CVD event (decrement in QOL for 3 months) 0.33 (0.11) [74]
*Figures for diabetics without albuminuria.All values are the same for diabetics with nephropathy, with the exception of relative risk of progression of kidney disease, as speciﬁed.
ACEi, angiotensin-converting enzyme inhibitor; CI, conﬁdence interval; CVD, cardiovascular disease; ESKD, end-stage kidney disease; QOL, quality of life; RR, relative risk.
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The effects of varying: 1) screening start age; and 2) screening
participation on the cost-effectiveness of screening programs
were also speciﬁcally assessed in deterministic one-way sensitiv-
ity analyses.
Results
Improved Management of Known Patients with Risk
Factors for CKD (“Treatment”)
Over a patient’s lifetime, intensive glycemic control of previously
uncontrolled diabetic patients resulted in cost savings, on
average, of $A133 compared with conventional management. It
resulted in an additional beneﬁt of 0.075 QALYs, meaning it was
both less costly and more effective than conventional manage-
ment. Cost savings were predominantly driven by the avoidance
of costly health outcomes such as cardiovascular events, deaths,
and the need for RRT. Over this time frame, for every 1000
patients managed intensively approximately six cardiovascular
deaths were prevented, one noncardiovascular death was pre-
vented, and there were approximately six fewer patients requir-
ing RRT for ESKD.
Over a comparable time period, intensive control of previ-
ously inadequately controlled hypertension cost an extra $A352,
and led to a gain of 0.136 QALYs, with an incremental cost-
effectiveness ratio (ICER) of $A2588 per QALY gained. For
every 1000 patients managed intensively over the duration of the
model, 19 cardiovascular deaths were prevented, 5 noncardio-
vascular deaths were averted, and there were 10 fewer patients
who required dialysis or transplant for ESKD.
The use of an ACE inhibitor by all diabetic patients led to
average cost savings of $825 over a patient’s lifetime, and a net
health gain of 0.124 QALYs; it was both more effective and less
expensive than current practice. For every 1000 diabetic patients
who received an ACE inhibitor, there were 18 fewer cardiovas-
cular deaths, 3 noncardiovascular deaths were prevented, and 9
fewer patients who developed ESKD and needed RRT. The addi-
tional small cost of an ACE inhibitor was more than offset by the
reduction in expensive cardiovascular events and progressions to
ESKD requiring RRT (Table 5).
Primary Care–Based Screening Strategies for CKD Risk
Factors (“Screening”)
Primary care–based screening for risk factors and intensive man-
agement of new and already identiﬁed, but inadequately con-
trolled, patients was also assessed.
Screening for diabetes between the ages of 50 and 69 years
had an incremental lifetime cost of $A1345, compared with
current practice, resulted in a gain of 0.098 QALYs, with an
ICER of $A13,781 per QALY gained. For every 1000 patients
screened for diabetes with detected cases managed with intensive
glycemic control, there were approximately two fewer cardiovas-
cular deaths, three fewer noncardiovascular deaths, and two
fewer patients requiring RRT for ESKD.
Screening for hypertension plus intensive blood pressure
management in new and already identiﬁed, but inadequately
controlled patients, had an incremental cost of $A57, resulted in
0.116 incremental QALYs, giving an ICER of $A491 per QALY
gained. For every 1000 patients screened for hypertension with
detected cases managed with intensive blood pressure control,
there were approximately nine fewer deaths from cardiovascular
disease, four fewer noncardiovascular deaths, and approximately
ﬁve fewer patients developing ESKD that needed RRT.
Screening for proteinuria plus the addition of an ACE inhibi-
tor for all diabetics and for persons with screen-detected pro-
teinuria had an ICER of $A4793 per QALY gained, compared
with current practice. For every 1000 patients screened for pro-
teinuria and treated with an ACE inhibitor, in combination with
treating all diabetic patients with an ACE inhibitor, there were
approximately three fewer deaths from cardiovascular disease,
one fewer death from noncardiovascular causes, and three fewer
patients that required RRT for ESKD (Table 5).
Sensitivity Analysis
Probabilistic sensitivity analysis—“treatment.” Cost-
effectiveness acceptability curves (Fig. 2a) indicate the probabil-
ity that an intervention is cost-effective, over a wide range of
funders’ willingness to pay for each additional health outcome.
Table 5 indicates the probability that treatment of risk factors is
Table 3 Screening test characteristics and costs
Value (%) Data source Total cost ($A 2008) Unit cost source
Population diabetes screening
Screen test sensitivity (FBSL) 86.7 89% [75]
US 83% [76]
Israel 95% [76]
$33.55 MBS item 23 [36]
$11.75 MBS item 66,503 [36]
Screen test speciﬁcity (FBSL) 65.5 59% [75]
US 76% [76]
Israel 47% [76]
Diagnostic test for screen-positive (oral glucose tolerance test) $33.55 MBS item 23 [36]
$19.30 MBS item 66,542 [36]
Population hypertension screening
Screen test sensitivity (mean of 3 measurements) 100 (assumed) $30.85 MBS item 23 [36]
Screen test speciﬁcity (mean of 3 measurements) 100 (assumed)
Screening for proteinuria
Screen test sensitivity (protein dipstick) 89 90% [23] $33.55 MBS item 23 [36]
90% (S. Chadban, personal
communication,AusDiab)
$1 [35]
Screen test speciﬁcity (protein dipstick) 94 67% [23]
94% (S. Chadban, personal
communication,AusDiab)
Diagnostic test for screen-positive (protein : creatinine ratio) $33.55 MBS item 23 [36]
$11.75 MBS item 66,503 [36]
FBSL, fasting blood sugar level; MBS, Medical Beneﬁts Schedule; US, United States.
CUA of CKD Risk Factor Screening and Management 201
Table 4 Resource use for treatment interventions and ESKD
Proportion of
patients
Average annual
per patient cost
for each class
($A 2008)
Total average
annual treatment
cost per patient
($A 2008)
Data source
for utilization
and unit costs
Intensive glycemic control
Drug costs [14, (A. Patel and
J. Chalmers.ADVANCE
Study: management
regimens in Australian
and New Zealand
patients. Personal
Communication)] [35]
Diet alone 0.033 $0.00 $0.00
Sulfonylureas incl gliclazide 0.9074 $151.22 $137.22
Metformin 0.708 $172.15 $121.88
TZD 0.179 $1,089.91 $195.09
Alpha-glucosidase inhibitors (acarbose) 0.0644 $874.41 $56.31
Glinides 0 $0.00 $0.00
Insulin 0.3328 $1,056.21 $351.51
Total proportion-weighted cost per patient $862
Other outpatient health-care utilization Use/patient/year Unit cost [36]
Consultation visits
Dietician 1 $57.55
GP visits 4—diet only $33.55 [18,36]
6—oral and/or insulin
Endocrinologist or diabetes clinic 1—diet only $139.45
2—oral and/or insulin
Podiatrist 1 $57.55
Nephrologist consult 0.1—diet only and oral $139.45
0.3—insulin
Ophthalmic consult 1 $139.45
Diagnostic tests
Home glucose test strips 26—diet and oral
(50% do 1/week)
$52.75
365—insulin (daily)
HbA1c done quarterly 4 $16.90
Other pathology (incl lipids, urinary albumin) 1 $15.75
Total proportion-weighted cost per patient
(3.3% diet, 63.4% oral, 33.3% insulin oral)
$910.20
Conventional glycemic control
Drug costs [14, (A. Patel and
J. Chalmers.ADVANCE
Study: management
regimens in Australian
and New Zealand
patients. Personal
Communication)] [35]
Diet alone 0.106 $0.00 $0.00
Sulfonylureas incl gliclazide 0.5674 $151.22 $85.80
Metformin 0.7003 $172.15 $120.55
TZD 0.1044 $1,089.91 $113.79
Alpha-glucosidase inhibitors (acarbose) 0.0337 $874.41 $29.47
Glinides 0 $0.00 $0.00
Insulin 0.1835 $1,056.21 $193.81
Total proportion-weighted cost per patient $543.43
Other outpatient health-care utilization
Regimens as per intensive for diet only, oral, and insulin As above As above As above [18,36]
Total proportion-weighted cost per patient
(10.6% diet, 71% oral, 18.4% insulin oral)
$765.73
Intensive hypertension control
Drug costs NEFRON [41]—
proportions in
patients with
hypertension [35]
Thiazides or other diuretics 0.36 $151.43 $53.86
Beta-blocker 0.27 $124.67 $33.82
ACE inhibitor 0.59 $237.77 $141.40
ARB 0.37 $350.47 $130.41
Fixed dose low dose thiazide + ACE 0.15 $351.49 $52.32
Fixed dose low dose thiazide + ARB 0.29 $393.23 $117.06
CCB 0.55 $266.29 $147.82
Alpha blocker 0.04 $264.51 $10.14
Total proportion-weighted cost per patient $686.82
Other outpatient health-care utilization Use/patient/year Unit cost [36]
GP visits 6 $33.55 $201.30
Other pathology (incl lipids, urinary albumin) 1 $15.75 $15.75
Total annual cost per patient $217.05
Conventional hypertension control
Drug costs [40]; [35]
Thiazides or other diuretics 0.14 $151.43 $21.20
Beta-blocker 0.24 $124.67 $29.92
ACE inhibitor 0.36 $237.77 $85.60
ARB 0.22 $350.47 $77.10
Fixed dose low dose thiazide + ACE 0.1 $351.49 $35.15
Fixed dose low dose thiazide + ARB 0.14 $393.23 $55.05
CCB 0.31 $266.29 $82.55
Alpha blocker 0.03 $264.51 $7.94
Total proportion-weighted cost per patient $394.51
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cost-effective at a threshold of $A50,000 per QALY gained
ranged from 84% to 88%. The probability that treatment inter-
ventions will save money ranged from 44% to 54% (Table 5 and
Fig. 2a–d).
Probabilistic sensitivity analysis—“screening.” Figure 3a and
Table 5 indicate that at a cost-effectiveness threshold of
$A50,000 per QALY gained, there is between a 50% and 57%
likelihood that screening and intensive management of risk
factors will have an ICER of less than $A50,000 per QALY
gained. The probability that screening interventions will save
money ranged from 21% to 31% (Table 5). Despite this, as can
be seen from Figure 3b–d, there is considerable uncertainty in the
estimates of incremental costs and incremental QALYs. The
uncertainty reﬂected here relates primarily to the uncertainty in
the estimates of effectiveness of the interventions for screen-
detected cases.
One-way sensitivity analyses. One-way sensitivity analyses indi-
cated the cost-effectiveness of screening improved as the starting
age increased, related primarily to increasing prevalence of
hypertension, diabetes, and proteinuria with increasing age. The
ICER increased slightly as participation increased, primarily
driven by the higher costs associated with higher participation
(Table 6).
Discussion
Our modeled analyses show that intensive treatment of patients
with inadequately controlled hypertension and/or diabetes, and
primary care–based screening for CKD and its major risk factors,
followed by intensive treatment, can lead to improved health
outcomes and are likely to represent good value for money. In
patients with existing diabetes, intensive management of patients
with uncontrolled blood glucose and the addition of an ACE
inhibitor in all patients appear to offer improved health outcomes
and lower long-term costs. Intensive hypertension management
also offers good value for money. In addition, primary care–
based screening and treatment for diabetes and for hypertension
and proteinuria also seem to offer better value for money com-
pared with many population screening programs already funded
in much of the developed world [47,48].
Table 4 Continued
Proportion of
patients
Average annual
per patient cost
for each class
($A 2008)
Total average
annual treatment
cost per patient
($A 2008)
Data source
for utilization
and unit costs
Other outpatient health-care utilization Use/patient/year Unit cost [36]
GP visits 4 $33.55 $134.20
Other pathology (incl lipids, urinary albumin) 1 $15.75 $15.75
Total annual cost per patient $149.95
Protein control (ACE inhibitor)
Patients with proteinuria and hypertension—intensive management
Drug costs (as for intensive hypertension management) $686.82 [35]
Other outpatient health-care utilization $217.05 [36]
Patients with proteinuria and hypertension—conventional management
Drug costs (as for conventional hypertension management) $394.51 [35]
Other outpatient health-care utilization $149.95 [36]
Patients with proteinuria and no hypertension—intensive management
Drug costs $237.77 [35]
ACE inhibitor only
Other outpatient health-care utilization $149.95 [36]
Dialysis costs
Hemodialysis
Initial hemodialysis access $15,490 [34]
Hospital hemodialysis $94,061 [34]
Home hemodialysis $51,782 [77]
Satellite hemodialysis $56,393 [77]
Peritoneal dialysis
Initial peritoneal dialysis access $12,762 [34]
Direct PD costs $64,221 [78]
Transplant costs
Live donor transplant
Surgery (recipient) $35,962 [34]
Surgery (donor) $13,836 [34]
Deceased donor transplant
Surgery (recipient) $35,962 [34]
Surgery (donor) $3,000 Expert opinion
Other resources: all transplants
Year of transplant
Immunosuppressive drug costs $19,038 [35]
Other drug costs $8,619 [35]
Other health-care resource use $6,428 [36]
Subsequent years
Immunosuppressive drug costs $8,881 [35]
Other drug costs $724 [35]
Other health-care resource use $819 [36]
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker (also known as angiotensin II-receptor antagonists); CCB, calcium channel blocker; ESKD, end-stage kidney disease;
GP, general practitioner; HbA1c, glycated hemoglobin; PD, peritoneal dialysis;TZD, thiazolidinediones.
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In adopting a risk factor-based approach, our analyses of
primary care–based interventions for CKD considered the com-
bined effects of screening and improving the current suboptimal
management of people with two chronic diseases. We modeled a
true population perspective by explicitly considering the age and
sex distribution of the population, the proportion of patients
with diagnosed and undiagnosed risk factors for CKD, and the
proportion of suboptimally controlled patients. We have applied
best-practice economic modeling techniques [49], utilizing a
probabilistic approach to characterize the joint parameter uncer-
tainty by incorporating distributions of both probabilities of
events, and of treatment effectiveness. Given the recent contro-
versy surrounding the beneﬁts of intensive glycemic control
[14,50], this probabilistic approach has explicitly modeled the
possibility of no treatment beneﬁt. As such, our analysis more
accurately estimates the costs and health outcomes at a whole of
population level.
There are few other cost-effectiveness estimates of these inter-
ventions in an Australian context. Our results are broadly con-
sistent with previous cost-effectiveness analyses of treatment
interventions for individual risk factors such as diabetes, hyper-
tension, and proteinuria for CKD [18–20,22,51], which have
reported ICERs ranging from interventions being both less costly
and more effective to ICERs greater than $US40,000 per QALY
gained for intensive glycemic control [19].
The results of our models also suggest that primary care
screening of 50- to 69-year-olds for diabetes, hypertension, and
proteinuria, with subsequent intensive management for all
screen-detected and suboptimally controlled patients, is likely to
offer good value for money in the Australian context, albeit
subject to some underlying uncertainty. Differences—in the
underlying modeled populations, in health systems, in delivery of
primary care, in the cost of care, and in the health outcomes
considered—all contribute to the variability in published ICERs.
Despite these differences, previous analyses also suggest that
screening for single risk factors may offer good value for money,
particularly for speciﬁc population subgroups. For example, a
trial-based analysis of screening for albuminuria with subsequent
fosinopril (PREVEND) reported an ICER of €16,700 per life-
year gained [52], although proteinuria screening for patients with
diabetes and comorbid hypertension had an ICER of $US20,011
per QALY gained [53]. ICERs for proteinuria screening, with
subsequent ACE inhibitor or ARB treatment ranged from
$US18,621 per QALY gained for patients with hypertension to
$US282,818 per QALY gained for people aged 50 years without
hypertension or diabetes [24].
Why is our estimate of the cost-effectiveness of screening for
proteinuria, then providing ACE inhibitor treatment for screen-
detected patients with proteinuria and known diabetics, more
favorable? First, the actual interventions and patient populations
modeled are different. Our intervention modeled ACE inhibitor
treatment for all screen-detected patients with proteinuria plus all
diabetic patients. We also report that ACE inhibitor treatment for
all patients with diabetes resulted in both a cost-saving and
additionalQALYs. Second, wemodeled general practice screening
and management, meaning the total cost of diagnostic assessment
for all screen-positive patients was $A45.30 (Table 3), compared
with higher estimates of specialist-based diagnostic assessment
$US2372 to $US2742 [24]. Third, the costs of pharmaceutical
management in our model were substantially lower (cost of ACE
inhibitors $A237 compared with $US390 to $US511 [24]).
Limited evidence regarding complex interplay between dia-
betes, hypertension, and proteinuria in CKD prevalence, risk of
progression, and effectiveness of screening and better manage-
ment, meant that our study was restricted to modeling costs andTa
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Intensive hypertension managementb c d
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Figure 2 (a) Cost-effectiveness acceptability curves for improved management strategies for existing patients. (b–d) Scatter plots of incremental costs and
incremental QALYs for improved management strategies for existing patients.ACEi, angiotensin-converting enzyme inhibitor; QALY, quality-adjusted life-year.
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Figure 3 (a) Cost-effectiveness acceptability curves for screening and improved management for new and existing patients. (b–d) Scatter plots of incremental costs
and incremental QALYs for screening and improved management for new and existing patients.ACEi, angiotensin-converting enzyme inhibitor;QALY, quality-adjusted
life-year.
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effects of single risk factor-based interventions. No data are
available on the combined effectiveness of multiple concurrent
strategies of risk factor management. Cost-effectiveness analyses
would ideally be based on randomized trial evidence of the
effectiveness of a “package” of interventions (screening and
better management) compared with routine management. Such a
trial has, however, has not been performed. Instead, we found it
necessary to synthesize the results of several independent trials
and meta-analyses. Robust data on the natural progression of
CKD from large-scale, population-based studies are only begin-
ning to become available. They will be crucial to the development
of screening and intervention strategies such as those modeled
here [54].
Using a health-care funder perspective meant that costs
related to productivity changes, and out of pocket costs to
patients and families, have not been included. It is possible that
cost-offsets from improved productivity as a result of avoiding,
or more actively managing, chronic disease may have been under-
estimated; however, these cost-offsets need to be balanced against
the additional costs to patients and families also not captured by
a health-care funder perspective. Our analyses speciﬁcally con-
sider the prevalence of risk factors in a representative Australian
population; in populations with a higher prevalence of CKD risk
factors, screening may well be more effective and cost-effective.
Similarly, our analysis is based on disease thresholds that may be
higher than would be used in current clinical practice. Lowering
the thresholds for risk factors would effectively increase the size
of the population considered to have the risk factor (in the
context of screening) or be “uncontrolled,” and therefore able to
beneﬁt from intensive intervention. The effect on the ICER of
lowering disease thresholds would depend upon both the relative
effectiveness of the interventions and the absolute risk of events
in this expanded population.
Conclusions
The rising prevalence of CKD and the ever-increasing demand for
high-cost dialysis and kidney transplant therapy require a full
exploration of a population-based approach to screening for, and
intensive treatment of, its risk factors. If a funder is willing to
spend up to $A50,000 for each additional QALY gained, a range
of strategies addressing intensive blood glucose and blood pres-
sure control among already identiﬁed patients, combined with
primary care screening of asymptomatic 50- to 69-year-olds for
diabetes, hypertension, and proteinuria, and subsequent optimal
care, should be strongly considered.
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Table 6 Cost-effectiveness of population screening strategies with alternative starting ages and screening participation
Screening intervention
Cost ($A 2008)
(intervention)
Cost ($A 2008)
(comparator)
Incremental
cost ($A 2008)
QALYs
(intervention)
QALYs
(comparator)
Incremental
QALYs
ICER ($ per
QALY gained)
Diabetes screening
Starting age for screening
30 $18,231 $16,487 $1,744 12.808 12.701 0.107 $16,299
40 $18,097 $16,487 $1,610 12.805 12.701 0.104 $15,481
50 (base-case) $17,832 $16,487 $1,345 12.798 12.701 0.097 $13,866
60 $17,495 $16,487 $1,008 12.789 12.701 0.088 $11,455
Screening participation (%)
25% $17,419 $16,487 $932 12.794 12.701 0.093 $10,022
50% $17,671 $16,487 $1,184 12.797 12.701 0.096 $12,333
75% (base-case) $17,832 $16,487 $1,345 12.798 12.701 0.097 $13,866
100% $17,931 $16,487 $1,444 12.8 12.701 0.099 $14,586
Hypertension screening
Starting age for screening
30 $14,302 $14,004 $298 12.955 12.831 0.124 $2,403
40 $14,183 $14,004 $179 12.946 12.831 0.115 $1,557
50 (base-case) $14,061 $14,004 $57 12.947 12.831 0.116 $491
60 $13,677 $14,004 -$327 12.953 12.831 0.122 Dominant
Screening participation (%)
25% $13,570 $14,004 -$434 12.953 12.831 0.122 Dominant
50% $13,803 $14,004 -$201 12.951 12.831 0.12 Dominant
75% (base-case) $14,061 $14,004 $57 12.947 12.831 0.116 $491
100% $14,194 $14,004 $190 12.953 12.831 0.122 $1,557
Proteinuria screening
Starting age for screening
30 $17,102 $16,821 $281 12.763 12.731 0.032 $8,781
40 $17,034 $16,821 $213 12.764 12.731 0.033 $6,455
50 (base-case) $16,974 $16,821 $153 12.763 12.731 0.032 $4,781
60 $16,897 $16,821 $76 12.764 12.731 0.033 $2,303
Screening participation (%)
25% $16,815 $16,821 -$6 12.764 12.731 0.033 Dominant
50% $16,856 $16,821 $35 12.763 12.731 0.032 $1,094
75% (base-case) $16,974 $16,821 $153 12.763 12.731 0.032 $4,781
100% $17,065 $16,821 $244 12.764 12.731 0.033 $7,394
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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